Thursday, March 13

Tag: PFE

A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?
27Dec By adminNo Comments
Money

A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

In pharma, you can take a larger slice of the healthcare pie than your peers, but you are still constrained by the size of the pie. No matter how good your cancer or diabetes drug is, healthcare systems will still have to keep paying for heart disease and rheumatoid arthritis treatments too.That, in a nutshell, is why the divergence of obesity-diabetes companies from the rest of the industry in recent years can’t go on forever. In 2023, Eli Lilly and Novo Nordisk have risen more than 50% each, to become the two largest pharma companies by market capitalization, with their combined value now hovering around $1 trillion. By comparison, the rest of the industry badly underperformed the market, with the NYSE Arca Pharmaceutical Index rising a measly 4% compared with 24% for the S&P 500.  ...
Read More
What the Supreme Court’s Decision Means for Abortion Pills
13Dec By adminNo Comments
World

What the Supreme Court’s Decision Means for Abortion Pills

Updated Dec. 13, 2023 6:22 pm ETThe Supreme Court said on Dec. 13 that it would weigh whether to limit access to mifepristone, a pill used in most abortions in the U.S.In April, the Biden administration and Danco Laboratories LLC, which sells the drug under the brand name Mifeprex, had appealed a ruling by the Fifth U.S. Circuit Court of Appeals that would have significantly affected the way mifepristone is used and dispensed for abortions. The Supreme Court blocked the lower court’s order while it decided whether or not to hear the case.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Earnings Estimates Are Falling. These Two Companies Are Shouldering the Blame.
14Nov By adminNo Comments
World

Earnings Estimates Are Falling. These Two Companies Are Shouldering the Blame.

Updated Nov. 14, 2023 4:19 pm ETWall Street has slashed its estimates for corporate profits in the final months of 2023. Yet investors appear to be taking the shifting picture in stride, partly because much of the blame appears to fall on just two companies: Pfizer and Merck. Analysts cut their projections for fourth-quarter earnings at companies in the S&P 500 by 3.9% in October, according to FactSet, more than twice the 10-year average of 1.8%. That marks the deepest reduction during the first month of a quarter in more than three years.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Earnings Estimates Are Falling. These Two Companies Are Shouldering the Blame.
14Nov By adminNo Comments
Money

Earnings Estimates Are Falling. These Two Companies Are Shouldering the Blame.

Updated Nov. 14, 2023 4:19 pm ETWall Street has slashed its estimates for corporate profits in the final months of 2023. Yet investors appear to be taking the shifting picture in stride, partly because much of the blame appears to fall on just two companies: Pfizer and Merck. Analysts cut their projections for fourth-quarter earnings at companies in the S&P 500 by 3.9% in October, according to FactSet, more than twice the 10-year average of 1.8%. That marks the deepest reduction during the first month of a quarter in more than three years.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Never Mind Covid, Investors Want a Pfizer Obesity Pill
31Oct By adminNo Comments
Money

Never Mind Covid, Investors Want a Pfizer Obesity Pill

Some of this year’s best performers in the healthcare sector are companies expected to profit from the anti-obesity drug craze, with Eli Lilly and Novo Nordisk shares both up more than 40% each. Much of the rest of the industry is underwater, with some of the biggest decliners being pandemic winners such as Pfizer and Moderna.It is little wonder, then, that investors were hoping Pfizer could jump to the winning camp with an obesity pill. But the company’s silence on its experimental oral medication, danuglipron, during its earnings release Tuesday, is worrying Wall Street. “Not one mention [of danuglipron] in the prepared remarks from Pfizer,” noted Will Sevush, a healthcare strategist for Jefferies. Before today’s earnings, David Risinger, a Leerink Partners analyst, had written that Pfi...
Read More
This $5 Billion Biotech Home Run Took Less Than a Year
25Oct By adminNo Comments
Money

This $5 Billion Biotech Home Run Took Less Than a Year

You can’t completely blame Pfizer’s executives, yet Roche’s $7 billion acquisition of a bowel-disease treatment that it owned until last year isn’t a great look.In a deal that now feels like a biotech version of “Moneyball,” Roivant announced it was selling an asset that only 11 months ago it got for free from Pfizer. (The Wall Street Journal had reported the talks back in July). Big pharma companies focused on the drug industry equivalent of free agent signings will often overlook one of their own hot prospects. In fact, Republican presidential candidate Vivek Ramaswamy founded Roivant on the idea that pharma’s trash can be another company’s treasure. But this one became an almost instant All-Star.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c...
Read More